Terms: = Prostate cancer AND ERCC3, RAD25, 2071, ENSG00000163161, GTF2H, TFIIH, BTF2, P19447, XPB AND Treatment
3 results:
1. DNA repair gene polymorphisms, tumor control, and treatment toxicity in prostate cancer patients treated with permanent implant prostate brachytherapy.
Carignan D; Lessard T; Villeneuve L; Desjardins S; Magnan S; Després P; Martin AG; Foster W; Guillemette C; Lévesque É; Vigneault E
Prostate; 2020 May; 80(8):632-639. PubMed ID: 32201973
[TBL] [Abstract] [Full Text] [Related]
2. Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant prostate cancer Cells.
Han Y; Huang W; Liu J; Liu D; Cui Y; Huang R; Yan J; Lei M
Theranostics; 2017; 7(7):1914-1927. PubMed ID: 28638477
[TBL] [Abstract] [Full Text] [Related]
3. prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer.
Thomsen FB; Christensen IJ; Brasso K; Røder MA; Iversen P
BJU Int; 2014 May; 113(5b):E98-105. PubMed ID: 24053601
[TBL] [Abstract] [Full Text] [Related]
